Adjuvant nab-paclitaxel plus S-1 versus oxaliplatin plus capecitabine after curative D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase 3 open-label, randomized controlled trial

被引：0
|
作者：
Yu Pengfei
Du, Yian
Xu, Zhiyuan
Yang, Litao
Ying, Jieer
Chen, Ping
Wei, Yunhai
Wu, Yingjie
Yan, Zhilong
Xu, Hongtao
Zhang, Xiaojing
Li, Yong
Zheng, Zhichao
Chen, Zhiheng
Cheng, Xiangdong
机构：
[1] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[2] Ningbo Second Hosp, Ningbo, Peoples R China
[3] Zhejiang Univ, Huzhou Hosp, Huzhou Cent Hosp, Huzhou, Peoples R China
[4] Ningbo Univ, Affiliated Peoples Hosp, Ningbo, Peoples R China
[5] Ningbo First Hosp, Ningbo, Peoples R China
[6] Lishui Cent Hosp, Lishui, Peoples R China
[7] Huzhou Teachers Coll, Affiliated Hosp, 1 Peoples Hosp Huzhou, Huzhou, Peoples R China
[8] Nanchang Univ, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China
[9] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[10] First Hosp Jiaxing, Jiaxing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
386
引用
收藏
页码：386 / 386
页数：1
相关论文
共 50 条
  • [31] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Yuan Zong
    Jiajia Yuan
    Zhi Peng
    Ming Lu
    Xicheng Wang
    Lin Shen
    Jun Zhou
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 1529 - 1536
  • [32] APACT: Phase III, Multicenter, International, Open-Label, Randomized Trial of Adjuvant nab-Paclitaxel Plus Gemcitabine (nab-P/G) Versus Gemcitabine (G) for Surgically Resected Pancreatic Adenocarcinoma
    Ko, A.
    Reni, M.
    Riess, H.
    Pelzer, U.
    O'Reilly, E. M.
    Winter, J.
    Oh, D. Y.
    Li, C. P.
    Tortora, G.
    Chang, H. M.
    Lopez, C. D.
    Tabernero, J.
    Van Cutsem, E.
    Philip, P.
    Goldstein, D.
    Berlin, J. D.
    Ferrara, S.
    Li, M.
    Lu, B.
    Romano, A.
    Marks, H.
    Biankin, A.
    Tempero, M. A.
    PANCREAS, 2019, 48 (10) : 1464 - 1464
  • [33] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study
    Zong, Yuan
    Yuan, Jiajia
    Peng, Zhi
    Lu, Ming
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (05) : 1529 - 1536
  • [34] Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
    Yu, Yuanyuan
    Zhang, Zicheng
    Meng, Qianhao
    Ma, Yue
    Fan, Xiaona
    Sun, Jie
    Wang, Guangyu
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] Neoadjuvant docetaxel, oxaliplatin plus capecitabine versus oxaliplatin plus capecitabine for patients with locally advanced gastric adenocarcinoma: long-term results of a phase III randomized controlled trial
    Tian, Yuan
    Yang, Peigang
    Guo, Honghai
    Liu, Yang
    Zhang, Ze
    Ding, Pingan
    Zheng, Tao
    Deng, Huiyan
    Ma, Wenqian
    Li, Yong
    Fan, Liqiao
    Zhang, Zhidong
    Wang, Dong
    Zhao, Xuefeng
    Tan, Bibo
    Liu, Yu
    Zhao, Qun
    INTERNATIONAL JOURNAL OF SURGERY, 2023, 109 (12) : 4000 - 4008
  • [36] Efficacy of S-1 or Capecitabine Plus Oxaliplatin Adjuvant Chemotherapy for Stage II or III Gastric Cancer after Curative Gastrectomy: A Systematic Review and Meta-Analysis
    Jeong, Sang-Ho
    Kim, Rock Bum
    Oh, Sung Eun
    An, Ji Yeong
    Seo, Kyung Won
    Min, Jae-Seok
    CANCERS, 2022, 14 (16)
  • [37] Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)
    Yamamoto, Tomohisa
    Fujii, Tsutomu
    Hirano, Satoshi
    Motoi, Fuyuhiko
    Honda, Goro
    Uemura, Kenichiro
    Kitayama, Joji
    Unno, Michiaki
    Kodera, Yasuhiro
    Yamaue, Hiroki
    Shimokawa, Toshio
    Hashimoto, Daisuke
    Yamaki, So
    Yoshitomi, Hideyuki
    Miura, Fumihiko
    Ueno, Hideki
    Sekimoto, Mitsugu
    Satoi, Sohei
    TRIALS, 2022, 23 (01)
  • [38] Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study)
    Tomohisa Yamamoto
    Tsutomu Fujii
    Satoshi Hirano
    Fuyuhiko Motoi
    Goro Honda
    Kenichiro Uemura
    Joji Kitayama
    Michiaki Unno
    Yasuhiro Kodera
    Hiroki Yamaue
    Toshio Shimokawa
    Daisuke Hashimoto
    So Yamaki
    Hideyuki Yoshitomi
    Fumihiko Miura
    Hideki Ueno
    Mitsugu Sekimoto
    Sohei Satoi
    Trials, 23
  • [39] Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
    Bekaii-Saab, Tanios
    Okusaka, Takuji
    Goldstein, David
    Oh, Do-Youn
    Ueno, Makoto
    Ioka, Tatsuya
    Fang, Weijia
    Anderson, Eric C.
    Noel, Marcus S.
    Reni, Michele
    Choi, Hye Jin
    Goldberg, Jonathan S.
    Oh, Sang Cheul
    Li, Chung-Pin
    Tabernero, Josep
    Li, Jian
    Foos, Emma
    Oh, Cindy
    Van Cutsem, Eric
    ECLINICALMEDICINE, 2023, 58
  • [40] Phase II feasibility study of adjuvant S-1 plus CPT-11 for stage III gastric cancer patients after curative D2 gastrectomy (OGSG 0801).
    Kimura, Yutaka
    Fujitani, Kazumasa
    Ueda, Shugo
    Taniguchi, Hirokazu
    Imamura, Hiroshi
    Gofuku, Junji
    Tamura, Shigeyuki
    Kurokawa, Yukinori
    Takiuchi, Hiroya
    Furukawa, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
12345